Advertisement|Remove ads.

Advertisement|Remove ads.
Shares of Basel Medical Group (BMGL) slumped more than 18% on Wednesday, reversing three sessions of gains, after the company said its board of directors approved a 1-for-12 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement of $1 per share.
The reverse stock split will take effect on June 22, 2026. It will be the firm’s first-ever share consolidation.
Under the reverse split, every 12 existing shares will be automatically consolidated into one share, reducing the number of outstanding shares from about 18.8 million to roughly 1.57 million. No fractional shares will be issued, the company added.
Advertisement|Remove ads.
In January, Basel Medical Group received a notice from Nasdaq stating that its shares had traded below the required minimum bid price of $1 for 30 consecutive business days. The company was given 180 days, or until July 21, 2026, to regain compliance.
According to its latest income statement for the year ended June 2025, the company reported a net loss of $8.4 million, compared with a loss of $1.5 million a year earlier. The stock currently has a short interest of 0.1%, its lowest in a year.
Retail sentiment for BMGL on Stocktwits turned ‘bullish’ from ‘extremely bullish’ a day earlier, while message volumes were ‘extremely high.’
Advertisement|Remove ads.
Investors saw the dip as an opportunity to buy, with one investor expecting a 20% to 50% return.
The stock has shed around 4% of its value so far this year.
Advertisement|Remove ads.
For updates and corrections, email newsroom[at]stocktwits[dot]com.
Comments posted here will also appear on symbol pages.